Equipment and Consumables posted 8.5% core sales growth, with high-single-digit growth in both consumables and diagnostics. Specialty Products & Technologies reported 3.1% core sales growth and nearly 6% total revenue growth. For implant VBP2, Envista expects a smaller price decline of approximately 10% to 15%. Excluding the calendar effect, the company expects fourth-quarter core growth to align with its full-year guidance range. Raised full-year outlookEnvista raised and narrowed its 2026 guidance, now expecting:Core sales growth of 3.5% to 4.5%.